BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 35167724)

  • 1. Protease-activated receptor-2 dependent and independent responses of bone cells to prostate cancer cell secretory products.
    Pagel CN; Kularathna PK; Sanaei R; Young ND; Hooper JD; Mackie EJ
    Prostate; 2022 May; 82(6):723-739. PubMed ID: 35167724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate cancer cells induce osteoblast differentiation through a Cbfa1-dependent pathway.
    Yang J; Fizazi K; Peleg S; Sikes CR; Raymond AK; Jamal N; Hu M; Olive M; Martinez LA; Wood CG; Logothetis CJ; Karsenty G; Navone NM
    Cancer Res; 2001 Jul; 61(14):5652-9. PubMed ID: 11454720
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts.
    Fizazi K; Yang J; Peleg S; Sikes CR; Kreimann EL; Daliani D; Olive M; Raymond KA; Janus TJ; Logothetis CJ; Karsenty G; Navone NM
    Clin Cancer Res; 2003 Jul; 9(7):2587-97. PubMed ID: 12855635
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Notch signaling and ERK activation are important for the osteomimetic properties of prostate cancer bone metastatic cell lines.
    Zayzafoon M; Abdulkadir SA; McDonald JM
    J Biol Chem; 2004 Jan; 279(5):3662-70. PubMed ID: 14602722
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Osteolytic prostate cancer cells induce the expression of specific cytokines in bone-forming osteoblasts through a Stat3/5-dependent mechanism.
    Schulze J; Albers J; Baranowsky A; Keller J; Spiro A; Streichert T; Zustin J; Amling M; Schinke T
    Bone; 2010 Feb; 46(2):524-33. PubMed ID: 19796718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-density lipoprotein receptor-related protein 5 (LRP5) mediates the prostate cancer-induced formation of new bone.
    Li ZG; Yang J; Vazquez ES; Rose D; Vakar-Lopez F; Mathew P; Lopez A; Logothetis CJ; Lin SH; Navone NM
    Oncogene; 2008 Jan; 27(5):596-603. PubMed ID: 17700537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proteinase-activated receptor-2 is required for normal osteoblast and osteoclast differentiation during skeletal growth and repair.
    Georgy SR; Pagel CN; Ghasem-Zadeh A; Zebaze RM; Pike RN; Sims NA; Mackie EJ
    Bone; 2012 Mar; 50(3):704-12. PubMed ID: 22173052
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The expression of osteoclastogenesis-associated factors and osteoblast response to osteolytic prostate cancer cells.
    Morrissey C; Lai JS; Brown LG; Wang YC; Roudier MP; Coleman IM; Gulati R; Vakar-Lopez F; True LD; Corey E; Nelson PS; Vessella RL
    Prostate; 2010 Mar; 70(4):412-24. PubMed ID: 19866469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vascular endothelial growth factor contributes to prostate cancer-mediated osteoblastic activity.
    Kitagawa Y; Dai J; Zhang J; Keller JM; Nor J; Yao Z; Keller ET
    Cancer Res; 2005 Dec; 65(23):10921-9. PubMed ID: 16322239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DU145 human prostate cancer cells express functional receptor activator of NFkappaB: new insights in the prostate cancer bone metastasis process.
    Mori K; Le Goff B; Charrier C; Battaglia S; Heymann D; Rédini F
    Bone; 2007 Apr; 40(4):981-90. PubMed ID: 17196895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bone Cell Activity in Clinical Prostate Cancer Bone Metastasis and Its Inverse Relation to Tumor Cell Androgen Receptor Activity.
    Nordstrand A; Bovinder Ylitalo E; Thysell E; Jernberg E; Crnalic S; Widmark A; Bergh A; Lerner UH; Wikström P
    Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29670000
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of prostate cancer osteoblastic progression with VEGF121/rGel, a single agent targeting osteoblasts, osteoclasts, and tumor neovasculature.
    Mohamedali KA; Li ZG; Starbuck MW; Wan X; Yang J; Kim S; Zhang W; Rosenblum MG; Navone NM
    Clin Cancer Res; 2011 Apr; 17(8):2328-38. PubMed ID: 21343372
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhancement of osteoclastogenic activity in osteolytic prostate cancer cells by physical contact with osteoblasts.
    Shiirevnyamba A; Takahashi T; Shan H; Ogawa H; Yano S; Kanayama H; Izumi K; Uehara H
    Br J Cancer; 2011 Feb; 104(3):505-13. PubMed ID: 21206493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of protease-activated receptor-2 leads to inhibition of osteoclast differentiation.
    Smith R; Ransjö M; Tatarczuch L; Song SJ; Pagel C; Morrison JR; Pike RN; Mackie EJ
    J Bone Miner Res; 2004 Mar; 19(3):507-16. PubMed ID: 15040840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate-specific antigen induces apoptosis of osteoclast precursors: potential role in osteoblastic bone metastases of prostate cancer.
    Goya M; Ishii G; Miyamoto S; Hasebe T; Nagai K; Yonou H; Hatano T; Ogawa Y; Ochiai A
    Prostate; 2006 Nov; 66(15):1573-84. PubMed ID: 16927388
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metastatic breast cancer cells suppress osteoblast adhesion and differentiation.
    Mercer RR; Miyasaka C; Mastro AM
    Clin Exp Metastasis; 2004; 21(5):427-35. PubMed ID: 15672867
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vascular endothelial growth factor contributes to the prostate cancer-induced osteoblast differentiation mediated by bone morphogenetic protein.
    Dai J; Kitagawa Y; Zhang J; Yao Z; Mizokami A; Cheng S; Nör J; McCauley LK; Taichman RS; Keller ET
    Cancer Res; 2004 Feb; 64(3):994-9. PubMed ID: 14871830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A proteome study of secreted prostatic factors affecting osteoblastic activity: galectin-1 is involved in differentiation of human bone marrow stromal cells.
    Andersen H; Jensen ON; Moiseeva EP; Eriksen EF
    J Bone Miner Res; 2003 Feb; 18(2):195-203. PubMed ID: 12568396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Substance P stimulates bone marrow stromal cell osteogenic activity, osteoclast differentiation, and resorption activity in vitro.
    Wang L; Zhao R; Shi X; Wei T; Halloran BP; Clark DJ; Jacobs CR; Kingery WS
    Bone; 2009 Aug; 45(2):309-20. PubMed ID: 19379851
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation of CD99/MIC2 expression of human AHTO-7 osteoblasts by carcinoma cell line-conditioned media.
    Hamilton D; Mallinger R; Millesi H; Engel A; Baumgartner G; Raderer M
    Anticancer Res; 2001; 21(6A):3909-13. PubMed ID: 11911268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.